NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan

Save

The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic

DMARD Efficacy in RA-ILD

Save

A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional, low-certainty recommendations.

The Power of Self-Management with Chronic Low Back Pain

Save

Almost everyone will deal with back pain at some point in their lives.

Uric Acid: Is Lower Better?

Save

Lowering serum urate and urate crystals in the body is indispensable for long-term management of gout. The pathophysiology is simple and powerful: no urate crystals, no gout flares.

ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis

Save

In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i recommendations.

EULAR26: ANCHOR-RA Study of RA-ILD

Save

People with rheumatoid arthritis are at risk of developing interstitial lung disease (RA-ILD), which is associated with high mortality.

ICYMI: Worldwide Trends in Hyperuricemia

Save

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA

Save

EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.

Insights into Treating Lupus - A Rheum Survey 

Save

RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.

EULAR26: GLP-1 Agonist Use in the RISE Registry

Save

At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). 

ICYMI: VEXAS Syndrome - A Review

Save

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.

ICYMI: Glucocorticoid Injections in Knee Osteoarthritis

Save

A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).

Spotlight on Comorbidities from EULAR 2026

Save

Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the risk of

ICYMI: EGPA Review

Save

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Save

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.